Toxicity grade during the treatment period
| . | No. of rituximab infusions = 583-150 . | |
|---|---|---|
| Grades 1 or 2 . | Grades 3 or 4 . | |
| Chills | 9 | 1 |
| Fever | 7 | 0 |
| Rhinitis | 3 | 0 |
| Pruritus | 3 | 0 |
| Nausea | 3 | 0 |
| Hypotension | 0 | 1 |
| Dizziness | 2 | 0 |
| Hyperventilation | 1 | 0 |
| Edema | 1 | 0 |
| Tachycardia | 2 | 0 |
| Vomiting | 1 | 0 |
| Paraesthesia | 1 | 0 |
| Hematological | 0 | 0 |
| Leukopenia | 2 | |
| Drop of CD20+ lymphocytes (counts not done in 4 patients) | 0 | 10 |
| . | No. of rituximab infusions = 583-150 . | |
|---|---|---|
| Grades 1 or 2 . | Grades 3 or 4 . | |
| Chills | 9 | 1 |
| Fever | 7 | 0 |
| Rhinitis | 3 | 0 |
| Pruritus | 3 | 0 |
| Nausea | 3 | 0 |
| Hypotension | 0 | 1 |
| Dizziness | 2 | 0 |
| Hyperventilation | 1 | 0 |
| Edema | 1 | 0 |
| Tachycardia | 2 | 0 |
| Vomiting | 1 | 0 |
| Paraesthesia | 1 | 0 |
| Hematological | 0 | 0 |
| Leukopenia | 2 | |
| Drop of CD20+ lymphocytes (counts not done in 4 patients) | 0 | 10 |
Number of adverse events during the treatment period. Symptoms were evaluated according to the National Cancer Institute's Adult Criteria.
The infusion of one patient had to be discontinued due to grade 3 toxicity. Her second rituximab dose was administered according to fractionated infusion schedule (one dose at two infusions on day 1 and 2) in order to minimize the severity of clinical adverse events.